30 closest matches · ranked by relevance
Lymphoma, Large-Cell, Anaplastic · Enteropathy-Associated T-Cell Lymphoma · Lymphoma, Large B-Cell, Diffuse
Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants
Lymphoma, B-Cell
Primary: Objective Response Rate (ORR) Using International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma as Assessed by Independent Central Review — 42.9…
Classical Hodgkin Lymphoma · Relapsed or Refractory Classical Hodgkin Lymphoma
Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months
Primary Mediastinal Large B Cell Lymphoma
Primary: Overall Objective Response Rate in Patients With Relapsed or Refractory PMLBCL — 11; 1; 1; 1 Participants
Mediastinal Large B-cell Lymphoma · Richter Syndrome
Primary: Objective Response Rate (ORR) Based on International Working Group (IWG) Response Assessment Criteria Per Independent Central Review — 45.3; 13.0 Percentage of…
Peripheral T Cell Lymphoma · Transformed Mycosis Fungoides
Primary: Overall Response Rate Assessed by Independent Review Committee Based on PET-CT — 32.4 percentage — p=0.051
Acute Lymphoid Leukemia · Acute Myeloid Leukemia · Anemia, Refractory, With Excess of Blasts
Primary: Objective Response Rate (ORR) by Investigator — 12; 14 percentage of participants
CD30 Positive Primary Mediastinal Large B-cell Lymphoma · CD30-Positive Diffuse Large B-Cell Lymphoma · CD30-Positive Gray Zone Lymphoma
Primary: Number of Subjects With Dose-limiting Toxicities — 0 Participants
T-cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepato-splenic T-cell Lymphoma
Primary: Overall Response Rate — 89.5 percentage of participants
Adult Diffuse Large Cell Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma · Stage IV Adult Diffuse Large Cell Lymphoma
Primary: Objective Tumor Response — 0 participants
Lymphoma, Large Cell, Diffuse · Lymphoma, Mixed Cell, Diffuse · Primary Mediastinal Large B-Cell Lymphoma
Primary: Progression-free Survival — 72 Percent
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Brain and Central Nervous System Tumors · Lymphoma
Primary: Number of Phase I Participants Experiencing Toxicity — 1; 3 Participants
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
Adult Lymphocyte Depletion Hodgkin Lymphoma · Adult Lymphocyte Predominant Hodgkin Lymphoma · Adult Mixed Cellularity Hodgkin Lymphoma
Primary: Number of Participants With Overall Response (OR) — 15; 4 participants
Diffuse Large B-Cell Lymphoma
Primary: Objective Response Rate (ORR) — 47.5; 46.2; 43.6 Percentage of participants — p=0.5543
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Non-Hodgkin's Disease
Primary: Safety Analysis - Number of Participants With Dose Limiting Toxicities (DLT) in the DLT Evaluation Phase — 0; 0; 0 Participants
Non-Hodgkin's Lymphoma
Primary: Overall Survival and Progression Free Survival — 73 percentage of patients
Hodgkin Disease · Peripheral T Cell Lymphoma
Primary: Objective Response Rate (ORR) According to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C) — 93; 95; 85 Percentage of participants
Diffuse Large B-cell Lymphoma
Primary: Disease-free Survival (DFS) — 77.8; 77.0 Percentage of participants — p=0.276
Peripheral T-cell Lymphoma
Primary: Progression-free Survival — 35; 27 participants
Lymphoma
Primary: 2-year Overall Survival Rate — 31 percentage of participants
Lymphoma, Non-Hodgkin · MALT Lymphoma
Primary: Objective Response Rate — .85 proportion of patients
EBV-Related Post-Transplant Lymphoproliferative Disorder · Monomorphic Post-Transplant Lymphoproliferative Disorder · Polymorphic Post-Transplant Lymphoproliferative Disorder
Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma · Peripheral T-Cell Lymphoma
Primary: Progression-free Survival After ASCT — 0.58; 0.77; 0.62 proportion of participants
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value